On Wednesday, November 13, 2024, at the Union World Conference on Lung Health held in Bali, Indonesia, the results of the Tuberculosis Trials Consortium (TBTC) Study 35 results were presented and confirmed the safety of the 3HP regimen in children ages 0-12 for the treatment of latent TB infection in both HIV-positive and HIV-negative patients. Furthermore, the study found methods in which to adapt dosages of the regimen by weight, meaning that an often overlooked yet highly vulnerable population now has a means to deal with tuberculosis earlier. Already these results are seeing a positive impact as the World Health Organization updated its global guidelines for the prevention of TB to include Study 35’s results. Heartland is proud to know that our own Dr. Barbara Seaworth was able to play a part in getting these results published. To see the official statement released by the Community Research Advisor’s Group (CRAG) via the official Treatment Action Group (TAG) website, please click on the image above.